{{Expand language|1=en|time=2020-08-18T08:57:50+00:00}}
{{Refimprove|time=2020-08-18T08:57:50+00:00}}

{{Infobox company
| name = 印度血清研究所
| name_en  = Serum Institute of India
| logo =
| logo_size = 250px
| logo_caption = Serum Institute of India
| type = 有限公司
| traded_as = 
| genre = <!--Only used with media and publishing companies -->
| fate = 
| predecessor = 
| successor = 
| foundation = <!-- {{Start date|df=yes|YYYY|MM|DD}} -->
| founder = {{link-en|Cyrus S. Poonawalla|Cyrus S. Poonawalla}}
| defunct = <!-- {{End date|df=yes|YYYY|MM|DD}} -->
| location = [[浦那|浦納]]，印度
| locations = 
| area_served = 世界範圍
| key_people = {{link-en|Adar Poonawalla|Adar Poonawalla}}
| industry = {{ubl|[[藥品|藥品]]|[[疫苗|疫苗]]}}
| products = 
| services = 
| revenue = {{increase}} 5.95億美元 (2015年)
| operating_income = 
| net_income = {{increase}} 2.95億美元 (2015年)
| aum = <!-- Only used with financial services companies -->
| assets = 
| equity = 
| owner = 
| num_employees = 
| parent = 
| divisions = 
| subsid = Vakzine Projekt Management GmbH<ref>{{Cite web|title=Profile|url=https://www.vpm-consult.com/en/company/profile/|access-date=2020-07-10|website=www.vpm-consult.com|archive-date=2021-02-06|archive-url=https://web.archive.org/web/20210206230016/https://www.vpm-consult.com/en/company/profile/|dead-url=no}}</ref> <ref>{{Cite web|title=Bilthoven Biologicals acquired by Serum Institute of India|url=https://www.thepharmaletter.com/article/bilthoven-biologicals-acquired-by-serum-institute-of-india|access-date=2020-07-10|website=www.thepharmaletter.com|archive-date=2021-02-06|archive-url=https://web.archive.org/web/20210206230013/https://www.thepharmaletter.com/article/bilthoven-biologicals-acquired-by-serum-institute-of-india|dead-url=no}}</ref>
| homepage = {{URL|https://www.seruminstitute.com/|seruminstitute.com}}
| footnotes = 
}}

'''印度血清研究所'''（{{lang-en|Serum Institute of India}}）是印度製藥企業，生產研發包括[[疫苗|疫苗]]在內的與[[免疫學|免疫學]]相關的藥物<ref>{{Cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=12168217|title=Serum Institute of India Pvt. Ltd.: Private Company Information|website=[[bloomberg.com|bloomberg.com]]|access-date=2018-09-30|archive-date=2018-09-30|archive-url=https://web.archive.org/web/20180930194629/https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=12168217|dead-url=no}}</ref><ref>{{Cite web|url=https://www.zaubacorp.com/company/SERUM-INSTITUTE-OF-INDIA-Private-Limited/U80903PN1984PTC032945|title=SERUM INSTITUTE OF INDIA PRIVATE LIMITED - Company, directors and contact details|website=zaubacorp.com|language=en|access-date=2018-09-30|archive-date=2021-02-06|archive-url=https://web.archive.org/web/20210206221759/https://www.zaubacorp.com/company/SERUM-INSTITUTE-OF-INDIA-Private-Limited/U80903PN1984PTC032945|dead-url=no}}</ref>。印度血清研究所於1966年創立<ref name="about">{{cite web |url=http://www.seruminstitute.com/content/about_us.htm |title=About Us |publisher=Serum Institute of India |accessdate=8 December 2016 |archive-date=2016-11-19 |archive-url=https://web.archive.org/web/20161119114224/http://www.seruminstitute.com/content/about_us.htm |dead-url=yes }}</ref>，目前是世界最大的疫苗生產商<ref>{{Cite web|title=Poonawalla Investments AND Industries Private Limited Information - Poonawalla Investments AND Industries Private Limited Company Profile, Poonawalla Investments AND Industries Private Limited News on The Economic Times|url=https://economictimes.indiatimes.com/company/|access-date=2020-07-10|website=The Economic Times|archive-date=2019-05-08|archive-url=http://webarchive.loc.gov/all/20190508200151/https://economictimes.indiatimes.com/company/|dead-url=no}}</ref><ref>{{cite web|url=https://www.forbes.com/profile/cyrus-poonawalla/|title=Cyrus Poonawalla on Forbes Lists|work=Forbes|accessdate=24 March 2015|archive-date=2020-12-30|archive-url=https://web.archive.org/web/20201230134433/https://www.forbes.com/profile/cyrus-poonawalla/|dead-url=no}}</ref>。該公司每年生產約13億劑疫苗<ref>{{Cite web|url=https://www.seruminstitute.com/product_ind_tubervac.php|title=Serum Institute Tubervac (BCG)|website=Serum Institute of India|access-date=2020-06-15|archive-date=2021-02-07|archive-url=https://web.archive.org/web/20210207135400/https://www.seruminstitute.com/product_ind_tubervac.php|dead-url=no}}</ref> <ref>{{Cite web|url=https://www.seruminstitute.com/product_ind_poliovac.php|title=Serum Institute Poliovac|website=Serum Institute of India|access-date=2020-06-15|archive-date=2021-02-06|archive-url=https://web.archive.org/web/20210206221747/https://www.seruminstitute.com/product_ind_poliovac.php|dead-url=no}}</ref> <ref>{{Cite web|url=https://www.iitk.ac.in/hc/vaccination-schedule|title=Vaccination Schedule|website=Vaccination as per the National Immunization schedule by Government of India|access-date=2020-06-15|archive-date=2021-02-06|archive-url=https://web.archive.org/web/20210206222701/https://www.iitk.ac.in/hc/vaccination-schedule|dead-url=no}}</ref>。

== 歷史 ==
印度血清研究所曾於2009年研發豬流感疫苗<ref>{{cite web|url=http://timesofindia.indiatimes.com/life-style/health-fitness/health/India-developing-indigenous-swine-flu-vaccine/articleshow/4873696.cms?referral=PM|title=India developing indigenous swine flu vaccine|work=The Times of India|accessdate=1 February 2015|archive-date=2018-10-01|archive-url=https://web.archive.org/web/20181001150024/https://timesofindia.indiatimes.com/life-style/health-fitness/health/India-developing-indigenous-swine-flu-vaccine/articleshow/4873696.cms?referral=PM|dead-url=no}}</ref><ref>{{cite journal |last1=Kulkarni |first1=Prasad S. |last2=Raut |first2=Sidram K. |last3=Dhere |first3=Rajeev M. |title=A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac ®) in India |journal=Human Vaccines & Immunotherapeutics |date=27 October 2014 |volume=9 |issue=1 |pages=122–124 |doi=10.4161/hv.22317 |pmid=23442586}}</ref>。2016年，在{{link-en|麻州大學醫學院|University_of_Massachusetts_Medical_School}}等的支持下，印度血清研究所研發了一種抗狂犬病藥物<ref>{{Cite web|url=http://timesofindia.indiatimes.com/city/pune/Fast-acting-anti-rabies-drug-set-for-India-launch/articleshow/51114312.cms|title=Fast-acting anti-rabies drug set for India launch - Times of India|website=The Times of India|access-date=2016-06-12|archive-date=2021-01-01|archive-url=https://web.archive.org/web/20210101153718/https://timesofindia.indiatimes.com/city/pune/Fast-acting-anti-rabies-drug-set-for-India-launch/articleshow/51114312.cms|dead-url=no}}</ref><ref>{{cite journal |last1=Kulkarni |first1=Prasad S. |last2=Sahai |first2=Ashish |last3=Gunale |first3=Bhagwat |last4=Dhere |first4=Rajeev M |title=Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd |journal=Expert Review of Vaccines |date=3 March 2017 |volume=16 |issue=4 |pages=303–311 |doi=10.1080/14760584.2017.1294068 |pmid=28276304}}</ref>。

== COVID-19疫苗 ==
2020年，印度血清研究所與英國-瑞典公司[[阿斯利康製藥|阿斯利康製藥]]合作，後者與[[牛津大學|牛津大學]]合作研發出[[AZD1222|AZD1222]]疫苗<ref>{{Cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine/articleshow/76202016.cms|title=AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine|work=The Economic Times|access-date=2020-06-15|archive-date=2021-02-22|archive-url=https://web.archive.org/web/20210222214731/https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine/articleshow/76202016.cms|dead-url=no}}</ref>，印度血清研究所獲得該疫苗的授權生產，並使用於印度及投放於世衛的全球疫苗分配計劃（[[COVAX|COVAX]]）。據報導，血清研究所將在印度和其他國家提供1億劑疫苗<ref>{{cite news |title=Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries |url=https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ |work=The Financial Express |date=7 August 2020 |accessdate=2020-08-18 |archive-date=2021-02-02 |archive-url=https://web.archive.org/web/20210202001740/https://www.financialexpress.com/lifestyle/health/covid-19-vaccine-serum-institute-signs-up-for-100-million-doses-of-vaccines-for-india-low-and-middle-income-countries/2047884/ |dead-url=no }}</ref><ref>{{cite news |last1=Banerjee |first1=Shoumojit |title=Oxford COVID-19 vaccine at least 6 months away from launch: Serum Institute CEO |url=https://www.thehindu.com/news/national/oxford-covid-19-vaccine-at-least-6-months-away-from-launch-serum-institute-ceo/article32015508.ece |work=The Hindu |date=7 July 2020 |language=en |accessdate=2020-08-18 |archive-date=2020-12-18 |archive-url=https://web.archive.org/web/20201218000831/https://www.thehindu.com/news/national/oxford-covid-19-vaccine-at-least-6-months-away-from-launch-serum-institute-ceo/article32015508.ece |dead-url=no }}</ref><ref>{{cite news |title=Coronavirus (Covid-19) vaccine latest update: Oxford-AstraZeneca corona vaccine production starts; US says 2 billion doses ‘ready to go’ |url=https://indianexpress.com/article/coronavirus/corona-covid-19-vaccine-update-june-oxford-astrazeneca-moderna-serum-institute-of-india-6447030/ |work=The Indian Express |date=10 June 2020 |language=en |accessdate=2020-08-18 |archive-date=2021-02-06 |archive-url=https://web.archive.org/web/20210206222353/https://indianexpress.com/article/coronavirus/corona-covid-19-vaccine-update-june-oxford-astrazeneca-moderna-serum-institute-of-india-6447030/ |dead-url=no }}</ref>。

2020年3月，印度血清研究所亦獲美國[[諾瓦瓦克斯醫藥|諾瓦瓦克斯醫藥]]授權，向發展中國家供應當時仍在研發的[[诺瓦瓦克斯2019冠状病毒病疫苗|NVX-CoV2373]]疫苗<ref>{{cite news |title=Novavax signs COVID-19 vaccine supply deal with India's Serum Institute |url=https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-signs-covid-19-vaccine-supply-deal-with-indias-serum-institute-idINKCN25139A |work=Reuters |date=2020-08-05 |accessdate=2021-04-06 |archive-date=2021-03-19 |archive-url=https://web.archive.org/web/20210319014912/https://www.reuters.com/article/us-health-coronavirus-novavax/novavax-signs-covid-19-vaccine-supply-deal-with-indias-serum-institute-idINKCN25139A |dead-url=no }}</ref>。

截至2021年3月，印度已經對76個國家發送超過6000萬劑疫苗<ref name="為貧窮國家尋找疫苗">{{cite news |title=世卫组织为较贫穷国家寻求1000万剂新冠疫苗 |url=https://chinese.aljazeera.net/news/2021/3/27/%E4%B8%96%E5%8D%AB%E7%BB%84%E7%BB%87%E4%B8%BA%E8%BE%83%E8%B4%AB%E7%A9%B7%E5%9B%BD%E5%AE%B6%E5%AF%BB%E6%B1%821000%E4%B8%87%E5%89%82%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97 |accessdate=2021-03-28 |work=半島電視台 |date=2021-03-27 |archive-url=https://web.archive.org/web/20210327114916/https://chinese.aljazeera.net/news/2021/3/27/%E4%B8%96%E5%8D%AB%E7%BB%84%E7%BB%87%E4%B8%BA%E8%BE%83%E8%B4%AB%E7%A9%B7%E5%9B%BD%E5%AE%B6%E5%AF%BB%E6%B1%821000%E4%B8%87%E5%89%82%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97 |archive-date=2021-03-27 |dead-url=no }}</ref>，印度血清研究所承擔向全球提供[[阿斯利康疫苗|阿斯利康疫苗]]的重任，並且是[[COVAX|COVAX]]疫苗分配機制最重要的供應者<ref name="聯合國新聞疫苗">{{cite news |title=新冠疫苗获取机制公布首份疫苗分配计划 预计今年上半年分发约3.37亿剂疫苗 |url=https://news.un.org/zh/story/2021/02/1077252 |accessdate=2021-03-28 |work=联合国新闻 |date=2021-02-03 |archive-date=2021-02-18 |archive-url=https://web.archive.org/web/20210218104727/https://news.un.org/zh/story/2021/02/1077252 |dead-url=no }}</ref>。

2021年4月開始，因[[2019冠狀病毒病印度疫情#2021年4月|印度國內陷入第二波爆發]]，政府下令禁止疫苗出口，包括印度血清研究所。<ref>{{Cite web|title=世界最大疫苗製造商陷困境，92 國等不到疫苗|url=https://technews.tw/2021/06/10/biggest-vaccine-maker-serum-problems-short-supply/|access-date=2021-06-10|work=TechNews 科技新報|language=zh-TW|archive-date=2021-06-13|archive-url=https://web.archive.org/web/20210613235743/https://technews.tw/2021/06/10/biggest-vaccine-maker-serum-problems-short-supply/|dead-url=no}}</ref>

==火災==
2021年1月21日下午，印度血清研究所一座在建建筑发生火灾，造成5人死亡<ref>{{Cite web |url=https://m.nbd.com.cn/articles/2021-01-22/1606607.html |title=印度血清研究所发生火灾，已致5人死亡，该所负责生产牛津大学和阿斯利康公司联合开发的新冠疫苗 |access-date=2021-01-22 |archive-date=2021-01-29 |archive-url=https://web.archive.org/web/20210129161209/https://m.nbd.com.cn/articles/2021-01-22/1606607.html |dead-url=no }}</ref>。

== 參見 ==
*[[COVAX|COVAX]]

== 參考資料 ==
{{reflist}}

[[Category:印度品牌|Category:印度品牌]]
[[Category:印度制药公司|Category:印度制药公司]]
[[Category:疫苗公司|Category:疫苗公司]]